Jilin Aodong released its 2026 interim report on August 29, 2026. During the reporting period, the company's total operating revenue was 1.031 billion yuan, down 8.47 percent from the same period last year, and net profit attributable to the parent company was 2.05 billion yuan. Net cash inflow from operating activities was 194 million yuan, the asset-liability ratio was 10.66 percent, gross margin was 47.14 percent, return on equity was 6.41 percent, and diluted earnings per share was 1.75 yuan. The company had 61,800 shareholders, and the top ten shareholders held 37.76 percent of total share capital.
Jilin Aodong Pharmaceutical Group Co LtdRevenue declined 8.47% year-over-year, though net profit was 2.05 billion yuan.
